Clinical Trials Logo

Arthritis, Rheumatoid clinical trials

View clinical trials related to Arthritis, Rheumatoid.

Filter by:

NCT ID: NCT04474912 Completed - Clinical trials for Rheumatoid Arthritis (RA) and Osteoarthritis (OA)

Serum IL-17 Correlated With Inflammatory Changes in Osteoarthritis and Rheumatoid Arthritis

Start date: July 1, 2020
Phase:
Study type: Observational

The total number of the included subjects was 120 in 3 equal groups (RA, OA and control). All subject was subjected to serum IL17 level measurement. MSK US (of both wrists, MCPs, PIPs and DIPs) was done to all patients in RA and OA groups. Disease activity was measured by disease activity score (DAS28) for RA patients. Visual analogue scale for pain (VAS) was obtained from patients in RA and OA groups. Functional assessment was done using health assessment questionnaire (HAQ) for RA patients and the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index for OA patients

NCT ID: NCT04472481 Completed - Clinical trials for Active Rheumatoid Arthritis

Vitamin D Effect in Rheumatoid Arthritis.

Start date: September 6, 2019
Phase: Phase 4
Study type: Interventional

Regulatory T (Tregs) cells play an important role in the maintenance of immunological tolerance. It decrease in the peripheral blood of rheumatoid arthritis patients. Vitamin D has an immunomodulatory and anti-inflammatory effect in rheumatoid arthritis. Vitamin D supplementation significantly enhances Tregs percentage in the peripheral blood of RA patients. So supplementation of Vit D improves rheumatoid arthritis disease activity.

NCT ID: NCT04464096 Completed - Clinical trials for Rheumatoid Arthritis

Can Musculoskeletal Ultrasound Predict Fall Risk in Rheumatoid Arthritis Patients?

Start date: April 10, 2018
Phase:
Study type: Observational

Rheumatoid patients have higher fall risk than normal population. Several fall risk factors were studied. No previous study investigated the role of musculoskeletal ultrasound as a predictor of fall risk in rheumatoid arthritis.

NCT ID: NCT04428424 Completed - Clinical trials for Arthritis, Rheumatoid

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Start date: July 5, 2020
Phase:
Study type: Observational

This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad Teaching Hospital registry.

NCT ID: NCT04426513 Completed - Clinical trials for Rheumatoid Arthritis

Magnetotherapy in Rheumatoid Arthritis Treatment

Start date: May 20, 2020
Phase: N/A
Study type: Interventional

Participants with rheumatoid arthritis with recommendation to physiotherapy. Created 3 study groups: 1. Only kinesiotherapy 2. Kinesiotherapy with unipolar magnetic field 3. Kinesiotherapy with bipolar magnetic field Kinesiotherapy with magnetic field give better effects than only kinesiotherapy.

NCT ID: NCT04413617 Completed - Clinical trials for Rheumatoid Arthritis

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Start date: July 29, 2020
Phase: Phase 2
Study type: Interventional

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

NCT ID: NCT04413448 Completed - Clinical trials for Rheumatoid Arthritis

Performance of CT Parameters Compared to Bone Mineral Density to Detect Bone Fragility in Rheumatoid Arthritis

Start date: January 1, 2020
Phase:
Study type: Observational

Objective: To evaluate the performance of CT parameters (SBAC-L1 and fractal analysis) compared to BMD (gold standard) to detect vertebral fractures in rheumatoid arthritis

NCT ID: NCT04407559 Completed - COVID-19 Clinical Trials

COVID-SErology in Rheumatoid Arthritis (COVID-19)

COVID-SERA
Start date: May 1, 2020
Phase:
Study type: Observational

Due to the Covid-19 worldwide outbreak, fragile patients with immune diseases, notably rheumatoid arthritis (RA), have to be even more specifically and carefully followed-up. However, it has been shown that false postive serological results often occured while detecting antibodies directed against SARS-CoV-2 in patients with positive rheumatodoid factor (RF). The investigators propose here to investigated this issue. Therefore, the investigators will test three different immunoassays on this specific population. The investigators aim to establish these assays specificity and the levels of RF for which there is a risk of anti-SARS-CoV-2 false positivity and thus ensure a better follow-up of RA patients. The RF isotype will be analysed to determine whether there is a correlation and the impact of the presence of anti-CCP (citrullinated cyclic antipeptide antibodies) will be studied and assessed.

NCT ID: NCT04389320 Completed - Clinical trials for Rheumatoid Arthritis

Antimalarial and Covid 19 in Rheumatoid Arthritis

Start date: March 15, 2020
Phase:
Study type: Observational

The antimalarial agent hydroxychloroquine(HCQ) have been used widely used for the treatment of rheumatoid arthritis and systemic lupus erythematosus. These compounds lead to improvement of clinical and laboratory parameters, but their slow onset of action differ them from glucocorticoids and nonsteroidal antiinflammatory agents. Among rheumatic diseases, the primary role of HCQ is in the management of articular and skin manifestations of systemic lupus erythematosus (SLE) and the treatment of mild to moderately active rheumatoid arthritis (RA).

NCT ID: NCT04356183 Completed - Clinical trials for Rheumatoid Arthritis

Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk

SWET/CHAT
Start date: July 21, 2021
Phase: N/A
Study type: Interventional

This is a small exploratory, randomized, controlled trial. Twenty-six older (ages 60-80 yr.), obese (BMI 28-40 kg/m2) persons with rheumatoid arthritis (RA) (seropositive or erosive) will be randomized to 16 weeks of a counseling health as treatment (CHAT) program or a supervised weight loss and exercise training (SWET) program.